

The Right Choice for the Critical Care Patient When Peripheral Venous Access is Not an Option



- Height: 5' 2"
- Weight: 82 lbs
- Heart Rate: 116
- BP: 152/71
- Creatinine: 1.9
- GFR: 70
- INR: 1.1
- No Fever

Case Study: Doris

Age: 71

Reason for Admission:

- Exacerbation Congestive Heart Failure (CHF).

History:

- Stroke 1 year ago
- Severe weakness in left arm
- Recent pneumonia treated with IV antibiotics via midline catheter 3 months ago – developed venous thrombosis in upper right arm and involving axillary area
- 2nd admission for CHF

Current Condition:

- Questionably stable
- Maintenance fluids
- Receiving furosemide IV

Current Department:

- CCU

Current Therapy Needs:

- Maintenance fluids, IV medications – the doctor has ordered low-dose dobutamine HCL continuously.
- Physician feels she is not a candidate for aquapheresis.
- If the patient improves, may discontinue to the nursing home with an order for intermittent/continuous dobutamine therapy.

Anticipated Length Of Vascular Device Dwell Time:

- Unknown (Weeks-to-months)

Potential Therapy Needs:

- Unknown

Discharged With The Line:

- Potential (Next steps: floor and then alternative site)

Order:

- PICC to be inserted by Vascular Access Team

When Peripheral Venous Access is Not an Option – The Critical Care Patient

Why use a Central Venous Catheter?

- History of upper extremity venous thrombosis in the patient's right arm
- Left arm weakness
- Poor peripheral veins
- Need for centrally placed catheter tip because of medication (vesicant/irritant)

Insertion Site Options:

Internal Jugular, Subclavian, Axillary

Why use the ARROW® JACC?

- Good candidate for single or dual-lumen catheter
- Smaller catheter size decreases the risk of venous thrombosis
- IJ may be site of choice – location and comfort
- One catheter to meet her vascular access needs from Critical Care through discharge

The Arrowg+ard Blue Advance™ JACC

The Arrowg+ard Blue Advance™ JACC (Jugular Axillo-subclavian Central Catheter) is the first and only long-term antimicrobial and antithrombogenic CVC. The ARROW JACC is a smaller French-size CVC protected with Arrowg+ard Blue Advance™ Protection, which helps prevent infection, occlusion, fibrin sheath and venous thrombosis for at least 30 days.^{1,2,3}

With these benefits, the ARROW JACC may dwell as long as your patient needs the catheter without ever changing to a secondary device. The ARROW JACC is designed to meet a patient's vascular access needs from the ICU through Outpatient Care. Get ready for a new paradigm in vascular access.



Discover the first and only long-term antimicrobial and antithrombogenic CVC.
Visit ARROWJACC.COM or call 800.523.8446

1 *In vitro* data on file.

2 As compared with uncoated Central Catheter, intravascular bovine model.

3 As compared to uncoated Central Line, *in vitro* model measuring flush pressure post exposure to human blood.

Rx only.

No correlation between *in vitro* / *in vivo* testing methods and clinical outcomes have currently been ascertained.

KDOQI is a trademark or registered trademark of the National Kidney Foundation, Inc.

Teleflex, Arrow, Arrowg+ard Blue Advance, and Never Settle are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

© 2018 Teleflex Incorporated. All rights reserved. MC-004533

ARROW®
NEVER SETTLE™